Loading...

Psychemedics Corporation

PMD•NASDAQ
Healthcare
Medical - Diagnostics & Research
$2.24
$-0.43(-16.10%)

Psychemedics Corporation (PMD) Stock Overview

Explore Psychemedics Corporation’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 61.0/100

Key Financials

Market Cap15.7M
P/E Ratio-8.46
EPS (TTM)$-0.51
ROE-0.33%
Fundamental Analysis

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 MonthsN/A
1 Year Target$1.24

PMD Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Psychemedics Corporation (PMD) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $1.24.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -8.46 and a market capitalization of 15.7M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Revenue Growth
-10.92%
↓ 10.92%
Profit Growth
$-0.32
↑ 55.20%
EPS Growth
$-0.32
↑ 55.56%
Operating Margin
-9.62%
↑ 35.19%
ROE
-32.94%
↑ 55.20%
Dividend Yield
0.00%
↓ 100.00%
Analyst Recommendations data is not available for PMDAnalyst Recommendations details for PMD are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States, Brazil, and internationally. The company offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opiates, such as heroin, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine and Fentanyl. Its testing results provide quantitative information that could indicate the approximate amount of drug ingested, as well as historical data that could show a pattern of individual drug use over a longer period-of-time. The company offers its services to employers for applicant and employee testing; and treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use. Psychemedics Corporation was incorporated in 1986 and is headquartered in Acton, Massachusetts.

CEO

Brian Hullinger

Employees

116

Headquarters

289 Great Road, Acton, MA

Founded

1987

Frequently Asked Questions

;